预测I-III期非小细胞肺癌的2年生存:澳大利亚队列评分系统的开发与验证
本研究基于三家放射肿瘤诊所2016年1月1日至2017年12月31日诊断的不可手术I-III期非小细胞肺癌患者数据,开发并验证了2年总生存预测模型——西南悉尼模型(SWSM)。模型在一家诊所(n=117)开发,在另两家诊所(n=144)验证,内部验证c-index为0.70,外部验证为0.72,可通过风险评分将生存概率分为三组。
要点
- SWSM包含五个变量:ECOG体能状态、肺一氧化碳弥散量、组织学诊断、肿瘤肺叶和2 Gy分次等效剂量。
- 模型内部验证c-index为0.70,外部验证c-index为0.72。
- 模型纳入肿瘤肺叶作为新变量,有潜力指导治疗决策,但需在更大患者队列中进一步验证。
核心结论
- 开发了一个具有良好区分度的2年生存模型,包含肿瘤肺叶这一新变量,有潜力指导治疗决策。
- 需在更大患者队列中进一步验证。
研究设计与样本
- 从三家放射肿瘤诊所收集2016年1月1日至2017年12月31日诊断的不可手术I-III期非小细胞肺癌患者数据。
- 采用单因素和多因素分析筛选变量,使用Cox比例风险回归开发2年总生存预测模型(SWSM),在一家诊所(n=117)开发,在另两家诊所(n=144)验证。
- 模型性能以Harrell一致性指数(c-index)表示,进行内部验证和一个独立数据集的外部验证。
主要发现
- SWSM包含五个变量:东部肿瘤协作组体能状态、肺一氧化碳弥散量、组织学诊断、肿瘤肺叶和2 Gy分次等效剂量。
- SWSM内部验证c-index为0.70,外部验证c-index为0.72。
- 使用模型衍生的风险评分可将生存概率分为三组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需在更大患者队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on survival prediction models in contemporary inoperable non-small cell lung cancer (NSCLC) patients. The objective of this study was to develop and validate a survival prediction model in a cohort of inoperable stage I-III NSCLC patients treated with radiotherapy. METHODS: Data from inoperable stage I-III NSCLC patients diagnosed from 1/1/2016 to 31/12/2017 were collected from three radiation oncology clinics. Patient, tumour and treatment-related variables were selected for model inclusion using univariate and multivariate analysis. Cox proportional hazards regression was used to develop a 2-year overall survival prediction model, the South West Sydney Model (SWSM) in one clinic (n = 117) and validated in the other clinics (n = 144). Model performance, assessed internally and on one independent dataset, was expressed as Harrell's concordance index (c-index). RESULTS: The SWSM contained five variables: Eastern Cooperative Oncology Group performance status, diffusing capacity of the lung for carbon monoxide, histological diagnosis, tumour lobe and equivalent dose in 2 Gy fractions. The SWSM yielded a c-index of 0.70 on internal validation and 0.72 on external validation. Survival probability could be stratified into three groups using a risk score derived from the model. CONCLUSIONS: A 2-year survival model with good discrimination was developed. The model included tumour lobe as a novel variable and has the potential to guide treatment decisions. Further validation is needed in a larger patient cohort.
引用
- Lee NS, Shafiq J, Field M, et al. Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort. Radiat Oncol. 2022. PMID: 35418206. doi:10.1186/s13014-022-02050-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。